Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxycycline + atorvastatin
- Development stage
- Unknown
- Lead developer
- Fayoum University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Topical
01
Overview
Doxycycline + atorvastatin is an investigational dual-drug nanoparticle formulation developed by Fayoum University for the local treatment of chronic periodontitis. The formulation consists of doxycycline, a tetracycline antibiotic and matrix metalloproteinase (MMP) inhibitor, and atorvastatin, a statin with anti-inflammatory and bone-regenerative properties, co-encapsulated in chitosan nanoparticles. This drug delivery system is designed for sustained release within periodontal pockets as an adjunct to scaling and root planing (SRP). Doxycycline provides antimicrobial activity against periodontal pathogens and inhibits MMP-8 to prevent connective tissue destruction, while atorvastatin promotes osteogenesis and reduces inflammation. It is currently being evaluated in a Phase 4 clinical trial for adults with stage II and III chronic periodontitis.
- Other names
- Doxycycline and Atorvastatin Loaded Chitosan NanoparticlesDoxycycline + Atorvastatin Nanoparticles
02
Targets
Bacterial RibosomeHMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)MMP8 (Neutrophil collagenase)
Beyond the preview
Go deeper on doxycycline + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxycycline + atorvastatin.